CCO Treatment Updates

The Great Debate: Treatment of HBV and the Impact on Transplantation

Update on Treatment Guidelines for Chronic Hepatitis B in the Transplant Setting

Module 1 of 3

Program Director:
Norah Terrault, MD, MPH

Faculty:

Norah Terrault, MD, MPH headshot
  • Norah Terrault, MD, MPH

CME CREDIT INFORMATION

Release Date: 05/20/05

Expiration Date: 05/19/06


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



Topics covered include:

  • Introduction
  • Treatment Goals in the Transplant Setting
  • Antiviral Options in Pre- and Post-Transplant Setting
  • Current Guidelines for Treatment of Patients With Cirrhosis
  • Current Guidelines for Treatment of Liver Transplant Recipients with Recurrent HBV Disease

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe optimal treatment for chronic hepatitis B in transplant recipients.

  • Review strategies for preventing recurrence of chronic hepatitis B in transplant recipients.

  • Discuss the current status of treatment guidelines for chronic hepatitis B in patients with cirrhosis.

What is the Optimal Duration of Antiviral Therapy in Patients with Hepatitis B-Related Cirrhosis?

Module 2 of 3

Program Director:
Norah Terrault, MD, MPH

Faculty:

Kris V. Kowdley, MD, FACP headshotK. Rajender Reddy, MD headshot
  • Kris V. Kowdley, MD, FACP
  • K. Rajender Reddy, MD

CME CREDIT INFORMATION

Release Date: 05/20/05

Expiration Date: 05/19/06


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status



Topics covered include:

  • Introduction
  • Optimal Duration of Therapy: It Should Be Indefinite, by K. Rajender Reddy, MD
  • Indefinite: Natural History
  • Indefinite: Candidates for Treatment
  • Indefinite: Treatment Endpoints

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the current status of treatment guidelines for chronic hepatitis B in patients with cirrhosis.

  • Describe optimal treatment for chronic hepatitis B with cirrhosis.

  • Evaluate strategies for preventing decompensation of chronic hepatitis B.

Management of HBV Reinfection Following Liver Transplantation

Module 3 of 3

Program Director:
Norah Terrault, MD, MPH

Faculty:

Robert J. Fontana, MD headshot
  • Robert J. Fontana, MD

CME CREDIT INFORMATION

Release Date: 05/20/05

Expiration Date: 05/19/06


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)

Registered Nurses: 1 Nursing CE credit

Status: Please log in to view status



Topics covered include:

  • Introduction
  • HBV Reinfection After Liver Transplantation
  • De Novo HBV Infection/Reactivation
  • Diagnosis and Clinical Course
  • Drug-Resistant HBV Mutants

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe optimal treatment for chronic hepatitis B in transplant recipients

  • Review strategies for preventing recurrence of chronic hepatitis B in transplant recipients

  • Discuss the current status of treatment guidelines for chronic hepatitis B in patients with cirrhosis

Interactive Case Challenges

A Middle-Aged Man with Chronic Hepatitis B Awaiting Transplantation

Program Director:
Norah Terrault, MD, MPH

Faculty:

Raymond T. Chung, MD headshot
  • Raymond T. Chung, MD

CME CREDIT INFORMATION

Release Date: 05/20/05

Expiration Date: 05/19/06


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



Evaluate the treatment options for a patient with hepatitis B infection awaiting liver transplantation

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe treatment options for chronic hepatitis B patients with decompensated cirrhosis.

  • Discuss management of HBV patients awaiting liver transplant, including localized treatment of hepatocellular carcinoma lesions.

  • Review data regarding the treatment of hepatitis B patients in the immediate post-transplant period.

A 43-Year-Old Liver Transplant Recipient with De Novo Hepatitis B Arising after Transplantation

Program Director:
Norah Terrault, MD, MPH

Faculty:

Raymond T. Chung, MD headshot
  • Raymond T. Chung, MD

CME CREDIT INFORMATION

Release Date: 05/20/05

Expiration Date: 05/19/06


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



Test your ability to manage a patient with de novo hepatitis B arising after liver transplantation.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the issue of nephrotoxicity in treatment of patients with de novo hepatitis B after liver transplantation

  • Describe data regarding the development of de novo hepatitis B after liver transplantation

  • Review data regarding the management of antiviral treatment for de novo hepatitis B after liver transplantation, including management of drug resistance

A 56-Year-Old Liver Transplant Recipient with Recurrent Hepatitis B

Program Director:
Norah Terrault, MD, MPH

Faculty:

Raymond T. Chung, MD headshot
  • Raymond T. Chung, MD

CME CREDIT INFORMATION

Release Date: 05/20/05

Expiration Date: 05/19/06


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



Manage the treatment of a patient with recurrent hepatitis B infection after liver transplantation.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss data regarding the use of hepatitis B immune globulin as prophylaxis against recurrent HBV in the post-transplant period

  • Review data regarding the management of nephrotoxicity in the post-transplant period

  • Describe methods of managing antiviral drug resistance in the post-transplant period

CCO Slidesets

Management of HBV Reinfection After Liver Transplantation (pdf format)


Format: Microsoft PowerPoint (.ppt) | File size: 345 KB


Update on Treatment of Chronic HBV in the Liver Transplant Setting


Format: Microsoft PowerPoint (.ppt) | File size: 894 KB


The Optimal Duration of Treatment for Chronic HBV Cirrhosis: Until Endpoints Are Reached


Format: Microsoft PowerPoint (.ppt) | File size: 413 KB


The Optimal Duration of Treatment for Chronic HBV Cirrhosis: Indefinite


Format: Microsoft PowerPoint (.ppt) | File size: 1,000 KB


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by University of Alabama School of Medicine and Clinical Care Options, LLC.

Nursing CE provided through the cosponsorship of Medical Education Collaborative and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.